Insider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells $5,769,300.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $576.93, for a total transaction of $5,769,300.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,890,130.68. This represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

James Edgemond also recently made the following trade(s):

• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.61, for a total transaction of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total transaction of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total transaction of $209,609.40.
• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total transaction of $5,513,815.56.
• On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.86, for a total transaction of $5,778,600.00.
• On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.18, for a total transaction of $5,771,800.00.
• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total transaction of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.89, for a total transaction of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $558.40, for a total transaction of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $561.50, for a total transaction of $5,615,000.00.

United Therapeutics Trading Down 4.6%

Shares of NASDAQ:UTHR opened at $569.18 on Friday. The company has a fifty day simple moving average of $550.17 and a 200 day simple moving average of $501.37. The firm has a market cap of $24.05 billion, a PE ratio of 21.01, a price-to-earnings-growth ratio of 1.70 and a beta of 0.60. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $6.63 EPS. As a group, equities research analysts forecast that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Torren Management LLC acquired a new position in shares of United Therapeutics during the fourth quarter valued at $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics during the fourth quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on UTHR. UBS Group lifted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Cantor Fitzgerald lifted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a report on Thursday. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Oppenheimer lifted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors focused on product/catalyst upside — market reaction was supported by management highlighting positive Tyvaso data in IPF and continued optimism around ralinepag’s blockbuster potential, which many say could drive significant future growth. UTHR Q1 Earnings Miss — Shares Jump on Strong Outlook
• Positive Sentiment: Partnership expansion with MannKind around DPI technology may improve delivery/manufacturing optionality and was reported to boost MannKind’s stock — a potential operational positive for United Therapeutics’ inhaled product ambitions. MannKind Stock Surges on Partnership
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly from $707 to $701 but retained an “outperform” rating, leaving a sizable implied upside from current levels; this is broadly supportive but not catalytic. RBC Lowers PT to $701
• Negative Sentiment: Q1 financials missed consensus: EPS of $5.82 vs. estimates near $7.00 and revenue $781.5M vs. ~$797M — revenue declined ~2% YoY. The miss can pressure short-term sentiment despite healthy margins. Q1 2026 Financial Results
• Negative Sentiment: Significant insider selling: CEO Martine Rothblatt sold 9,500 shares (~19% reduction in her disclosed holding) and EVP Paul Mahon sold 8,300 shares (~15.5% reduction). Large, contemporaneous insider reductions can weigh on sentiment, especially after an earnings miss. Rothblatt SEC Filing Mahon SEC Filing

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.